Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telotristat etiprate - Lexicon Pharmaceuticals

Drug Profile

Telotristat etiprate - Lexicon Pharmaceuticals

Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Xermelo

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin modulators; Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Phase II Biliary cancer
  • Discontinued Ulcerative colitis

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for phase-I development in malignant carcinoid syndrome in Moldova (PO, Tablet)
  • 15 Mar 2019 Phase-II clinical trials in Biliary cancer (Late-stage disease, Combination therapy, Metastatic disease, Locally recurrent) in USA (PO) (NCT03790111)
  • 13 Mar 2019 Launched for Malignant carcinoid syndrome (Adjunctive treatment, Treatment-experienced) in Belgium, Northern Ireland, Luxembourg, Greece, Denmark, the Netherlands (PO) before March 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top